KRAS G13C [plasma membrane]

Stable Identifier
R-HSA-9649636
Type
Protein [EntityWithAccessionedSequence]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
17504988 KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Massarelli, E, Herbst, RS, Xavier, AC, Tang, X, Liu, DD, Ozburn, NC, Varella-Garcia, M, Bekele, BN, Wistuba, II

Clin. Cancer Res. 2007
18621636 Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

Amado, RG, Radinsky, R, Sarosi, I, Hecht, JR, Berlin, J, Juan, T, Meropol, NJ, Freeman, DJ, Mitchell, E, Reiner, M

Clin Colorectal Cancer 2008
Participates
Other forms of this molecule
Modified Residues
Name
glycine 13 replaced with L-cysteine
Coordinate
13
PsiMod
A protein modification that effectively removes or replaces an glycine.
A protein modification that effectively converts a source amino acid residue to an L-cysteine.
Cross References
Guide to Pharmacology - Targets
OpenTargets
ZINC - Substances
ZINC target
PRO
PDB
6VC8, 6O4Y, 8FMK, 5MLB, 8I5E, 4Q02, 5US4, 8TXE, 4NMM, 8V39, 6OB2, 4LDJ, 6CU6, 1KZO, 8BLR, 6WS4, 7W5R, 6BP1, 6O36, 6ZLI, 6V5L, 8AQ5, 6PTW, 6CC9, 8TBJ, 4M1S, 9BHP, 7SCW, 4WA7, 6GQW, 5XCO, 5YY1, 3GFT, 7LGI, 7U8H, 8G9P, 8B69, 8DNI, 4EPT, 8G47, 7R0M, 5UFE, 4Q01, 5MLA, 5WHD, 8I5D, 6O51, 6MQG, 8F0M, 6EPL, 8ONV, 8T74, 6EPO, 5WLB, 6FA3, 5UK9, 8DGS, 7A47, 7LC2, 8JHL, 7RP2, 7ACH, 5V6V, 8STN, 4PZZ, 6GJ7, 8AFB, 5W22, 5VPY, 4LPK, 7RT1, 7C41, 6CCH, 6GQT, 6GOE, 8T4V, 1D8D, 4EPY, 8CPR, 6ZL5, 6M9W, 2MSE, 8I5C, 8CX5, 6XHB, 8BE4, 7NY8, 8UN4, 7TLK, 8TXG, 6W4E, 8G42, 8AZX, 8T73, 6E6F, 4LYJ, 8TXH, 4DSO, 6FA4, 8V3A, 6USZ, 4PZY, 6T5U, 8AQ7, 4Q03, 9BFY, 8STM, 5VQ2, 7A1Y, 5O2S, 8TBN, 1N4P, 6V65, 8VGQ, 5VPI, 6P8Z, 6B0V, 6QUW, 8TBM, 8G4H, 4EPR, 4EPX, 5OCG, 6JTN, 8VRA, 7F0W, 6MS9, 7EW9, 6WS2, 8UN3, 8EIE, 8BE3, 6O4Z, 8FMJ, 5TB5, 8VRB, 8T75, 8QU8, 9AX6, 8YIV, 6EPP, 8JJS, 8TY2, 6H46, 5VBM, 4LYH, 7ACQ, 6T5V, 8UN5, 7KMR, 5V9O, 6GJ8, 5VPZ, 6QUU, 8JGD, 7RT4, 9BHO, 8TBL, 7C40, 6E6G, 5VQ0, 7A1W, 6JTP, 8EER, 6P8X, 6XGU, 7RPZ, 8DNK, 8VJZ, 4M1W, 6ASA, 6JTO, 8FMI, 6XHA, 5WHE, 6O46, 4DSN, 8AZR, 8YJ2, 8RRO, 6W4F, 6FA1, 4L8G, 8EZG, 8TXK, 8ECR, 7KYZ, 4OBE, 8R7X, 7ACF, 6H47, 5V9L, 6GJ5, 6TAM, 6PTS, 8TBF, 6GOF, 5OCO, 5YXZ, 8AFD, 9BI2, 4M22, 7VVB, 6GQX, 5VQ1, 7RSC, 1N4Q, 6MBU, 7A1X, 7RT5, 8PIY, 4EPW, 6UT0, 8DNJ, 6XGV, 6ARK, 6N2J, 5V71, 8EBZ, 7R0Q, 8TY8, 6EPM, 8AZZ, 7YCC, 5WHB, 6CCX, 4LUC, 4LYF, 6O53, 5USJ, 5WPM, 8R7W, 5F2E, 6OIM, 8TVK, 6USX, 6TAN, 6OB3, 8T72, 8PI0, 5VQ8, 8QW7, 7Q9U, 4M1Y, 5VP7, 9BHQ, 4TQA, 6GQY, 8TBH, 7RT3, 8QUG, 1N4R, 7RSE, 5VQ6, 7OK4, 6P8Y, 5KYK, 5O2T, 2MSC, 6VJJ, 6PQ3, 5TAR, 7TLG, 8WUL, 6MQN, 8BE5, 7YUZ, 7LC1, 8B6I, 7EWB, 6MNX, 8AZY, 8T71, 7YV1, 5UQW, 8EPW, 8DGT, 6BOF, 8TXJ, 7MQU, 4QL3, 7RP4, 6GJ6, 7KFZ, 7LZ5, 6MTA, 5UFQ, 8B78, 9BG1, 6GOG, 8EDY, 4M21, 8QW6, 8G4F, 7T1F, 6P8W, 6MBQ, 8B00, 5OCT, 1N4S, 8G9Q, 7T47, 6QUX, 4M1T, 6YR8, 6PGO, 7EYX, 8TBK, 7ROV, 6B0Y, 7O70, 5WHA, 6YXW, 6ASE, 6N2K, 7EWA, 6EPN, 6FA2, 7STF, 6T5B, 5V6S, 7MDP, 6V6F, 8TY9, 7YCE, 7ACA, 7OO7, 6WGN, 1KZP, 8AZV, 7TLE, 6F76, 7RP3, 5V9U, 8UDR, 4LRW, 8AFC, 6MBT, 4TQ9, 8QVU, 1D8E, 7SCX, 8VR9, 8DVG, 7RT2, 9BI1, 8S8C, 6PGP, 6P0Z, 6GOD, 7OK3, 6QUV, 6GOM, 4M1O, 7R0N, 2MSD, 8WTE, 4EPV, 8X6R, 4LV6
COSMIC
GeneCards
Pharos - Targets
Orphanet
HMDB Protein
Interactors (13)
Accession #Entities Entities Confidence Score Evidence (IntAct)
 UniProt:P04049 RAF1  20 0.695 6
 UniProt:P15056 BRAF  20 0.68 5
 UniProt:Q99755 PIP5K1A  1 0.661 9
 UniProt:Q96II5 Q96II5      0.556 3
 UniProt:P50749 RASF2      0.544 2
 UniProt:P61586 RHOA  6 0.519 2
 UniProt:O75915 ARL6IP5  1 0.519 2
 UniProt:P10398 ARAF  4 0.483 2
 UniProt:Q9UQB8 BAIAP2  1 0.483 2
 UniProt:P28288 ABCD3  2 0.483 2
 UniProt:P01111 NRAS  20 0.483 2
 UniProt:Q7KZI7 MARK2      0.483 2
 ChEBI:16618 1-PHOSPHATIDYL-1D-MYO-INOSITOL 3,4,5-TRISPHOSPHATE      0.462 2
Cite Us!